naion with tirzepatide While GLP-1 drugs have been used by millions of people around the world for both weight loss and diabetes control, there may be risks associated. , One vision risk is the potential link between GLP-1 Semaglutide Once Again Linked to

-Helps in reducing aging

Mirand, P

Conclusion Research suggests that GLP-1 receptor agonists like semaglutide and tirzepatide can significantly improve OSA severity, primarily through substantial weight loss that reduces fat deposits around the upper airway

Many authors discuss the inadequacy of guidelines when written based on general consensus and expert opinion, rather than on high-level clinical evidence, noting that case reports, retro/prospective studies, and observational studies, as is mostly what is currently available, are often insufficient to inform clinical practice (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)